TY - JOUR T1 - Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers JF - Exp Hematol Y1 - 1996 A1 - Huhn,R. D. A1 - Yurkow,E. J. A1 - Tushinski,R. A1 - Clarke,L. A1 - Sturgill,M. G. A1 - Hoffman,R. A1 - Sheay,W. A1 - Cody,R. A1 - Philipp,C. A1 - Resta,D. A1 - George,M. KW - Adult KW - Antigens, CD34 / analysis KW - Antigens, Thy-1 / analysis KW - Colony-Forming Units Assay KW - Drug Synergism KW - Female KW - Filgrastim KW - Granulocyte Colony-Stimulating Factor / *pharmacology KW - Hematopoietic Stem Cells / *drug effects KW - Humans KW - Interleukin-3 / *pharmacology KW - Leukapheresis KW - Leukocyte Count / drug effects KW - Male KW - Recombinant Proteins / pharmacology KW - Safety AB - To identify a precisely timed and safe protocol for progenitor cell mobilization, we studied the effects of rhIL-3 and rhG-CSF administration to normal volunteers. rhG-CSF 5 micrograms/kg/d was administered subcutaneously (s.c.) for 7 consecutive days either alone or preceded by rhIL-3 5 micrograms/kg/d s.c. for 4 consecutive days in sequential or partially overlapping schedules. The combined cytokines were well-tolerated--adverse effects were similar to those of the individual agents. Total white blood cell (WBC) and neutrophil counts rose briskly in response to rhG-CSF, and peak mean values were similar between treatment cohorts. Mean platelet counts were modestly elevated during rhG-CSF treatment only in the cohorts receiving rhIL-3 and rhG-CSF. Mean circulating CD34+ cells peaked on day 5 in the rhG-CSF group (38.9+/-14.3/microliter), day 6 in the sequential rhIL-3/rhG-CSF group (56.4+/-12.4/microliter), and day 6 in the partial overlap group (46.1+/-10.9/microliter). On day 3, mean CD34+ cell counts of the subjects who received sequential treatment were markedly higher than observed in the other groups (p<0.05) and were estimated to have been sufficient for collection of adequate grafts by single 10-L leukapheresis procedures in 60% of subjects. Circulating clonogenic cells (CFU-GM and/or BFU-E) were substantially higher in the sequential group than the rhG-CSF group on days 3-6 but were only minimally elevated above baseline in the partial overlap group. The numbers of circulating CD34+/Lin-/Thy-1+ cells (putative stem cells) were increased substantially, especially in the sequential group. On the basis of this pilot trial, we conclude that priming with rhIL-3 is a safe and well-tolerated method for enhancing the mobilization of human blood progenitors and stem cells by rhG-CSF. VL - 24 CP - 7 N1 - Huhn, R D Yurkow, E J Tushinski, R Clarke, L Sturgill, M G Hoffman, R Sheay, W Cody, R Philipp, C Resta, D George, M Comparative Study Research Support, Non-U.S. Gov't United states Experimental hematology Exp Hematol. 1996 Jun;24(7):839-47. ID - 701 ER -